No effect of Parkinson’s disease-polygenic load on striatal density of dopaminergic neuron in healthy subjects
暂无分享,去创建一个
[1] Jong Hun Kim,et al. Effect of polygenic load on striatal dopaminergic deterioration in Parkinson disease , 2019, Neurology.
[2] Myung Jun Lee,et al. Effect of Single-Nucleotide Polymorphisms on Decline of Dopamine Transporter Availability in Parkinson's Disease , 2018, Journal of clinical neurology.
[3] D. Berg,et al. Polygenic load: Earlier disease onset but similar longitudinal progression in Parkinson's disease , 2018, Movement disorders : official journal of the Movement Disorder Society.
[4] Myung Jun Lee,et al. Effects of rs591323 on serotonin transporter availability in healthy male subjects , 2018, Annals of Nuclear Medicine.
[5] A. Singleton,et al. Genetic risk factors in Parkinson’s disease , 2018, Cell and Tissue Research.
[6] M. Nalls,et al. A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci , 2017, Nature Genetics.
[7] S. Aoki,et al. Age-related effects and gender differences in Japanese healthy controls for [123I] FP-CIT SPECT , 2017, Annals of Nuclear Medicine.
[8] M. Trost,et al. Genetic Determinants of Parkinson's Disease: Can They Help to Stratify the Patients Based on the Underlying Molecular Defect? , 2017, Front. Aging Neurosci..
[9] D. Hernandez,et al. Baseline genetic associations in the Parkinson's Progression Markers Initiative (PPMI) , 2016, Movement disorders : official journal of the Movement Disorder Society.
[10] M. Vidailhet,et al. Dopaminergic denervation severity depends on COMT Val158Met polymorphism in Parkinson's disease. , 2015, Parkinsonism & related disorders.
[11] A. Waldman,et al. The Role of Functional Dopamine-Transporter SPECT Imaging in Parkinsonian Syndromes, Part 1 , 2015, American Journal of Neuroradiology.
[12] Chuong B. Do,et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease , 2014, Nature Genetics.
[13] Y. Okubo,et al. Age-related decline in dopamine transporter in human brain using PET with a new radioligand [18F]FE-PE2I , 2014, Annals of Nuclear Medicine.
[14] J. Foster,et al. Mechanisms of dopamine transporter regulation in normal and disease states. , 2013, Trends in pharmacological sciences.
[15] Chuong B. Do,et al. Comprehensive Research Synopsis and Systematic Meta-Analyses in Parkinson's Disease Genetics: The PDGene Database , 2012, PLoS genetics.
[16] C. Duyckaerts,et al. The second brain and Parkinson’s disease , 2009, The European journal of neuroscience.
[17] Frank Baas,et al. Striatal Dopamine Transporter Availability Associated with Polymorphisms in the Dopamine Transporter Gene SLC6A3 , 2008, Journal of Nuclear Medicine.
[18] Donald Grosset,et al. Role of dopamine transporter imaging in routine clinical practice , 2003, Movement disorders : official journal of the Movement Disorder Society.
[19] Patrik Brundin,et al. Pathogenesis of parkinson's disease: dopamine, vesicles and α-synuclein , 2002, Nature Reviews Neuroscience.
[20] J D Speelman,et al. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. , 1997, Journal of neurology, neurosurgery, and psychiatry.
[21] K. Laere,et al. European multicentre database of healthy controls for [123I]FP-CIT SPECT (ENC-DAT): age-related effects, gender differences and evaluation of different methods of analysis , 2012, European Journal of Nuclear Medicine and Molecular Imaging.
[22] Patrik Brundin,et al. Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. , 2002, Nature reviews. Neuroscience.